pharma · Hyperbilirubinemia
Mallinckrodt Pharmaceuticals
Mallinckrodt Pharmaceuticals Ireland Limited
Mallinckrodt Pharmaceuticals Ireland is a pharma organization headquartered in DUBLIN, IE. Primary therapeutic focus areas include Hyperbilirubinemia. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0
Dublin, IE HQ
1867 Founded
2,708 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Dublin, IE
- Founded
- 1867
- Employees
- 2,708
- Programs
- 1
- Drugs
- 0
- Patents
- 0
Stanate
Phase 2 · small molecule · Hyperbilirubinemia
Stanate for Hyperbilirubinemia is a Phase 2 program (small_molecule) at Mallinckrodt Pharmaceuticals Ireland Limited with 1 ClinicalTrials.gov record(s).
Internal code 64,185-06-2W
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Mallinckrodt Pharmaceuticals Ireland Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Hyperbilirubinemia
- Status
- completed
- Trials
- 1